

Update from the 2010 National Influenza Vaccine Summit meeting

L.J Tan

Co-chair, National Influenza Vaccine Summit
Director, Medicine and Public Health, AMA

The National Influenza Vaccine Summit is...

- Co-sponsored by AMA and CDC
- A partnership of more than 130 organizational stakeholders, both private and public, in influenza vaccine research, production, distribution, advocacy, and administration
- All committed to achieving the Healthy People 2010/2020 goals for influenza vaccine
- Contact L.J Tan (Litjen.Tan@ama-assn.org) for more information

The Summit is also...

- An annual meeting
- A concept
- An informal, action-oriented organization
- A tool for improving communications between stakeholders
- A resource

Members of the Summit include...

- Vaccine Manufacturers
- Vaccine Distributors
- Federal Agencies
- Professional Medical Organizations
 - Specialty
 - State
- Nursing Organizations
- Public Health
- Hospitals

Members of the Summit include...

- Pharmacists
- Community Immunization Providers
- Occupational Health Providers
- Business/Employers
- Private Health Insurance and Managed Care
- Long-term Care
- Quality Improvement Organizations
- Consumers
- Advocacy Groups

Summit Creates United Influenza Vaccination Goals

- Improve transparency and communications between partners around influenza vaccine supply and distribution
- Increase awareness about severity of influenza, benefits of vaccination throughout season
- Advocacy to change policy
- Achieve national/local media coverage
 - Annual Summit awards
- Provide timely communications between Influenza Vaccine Summit stakeholders
 - Email Updates, weekly conference calls
 - Extend communications messages to the grassroots levels

The May 17 -19, 2010 Summit Meeting

- Almost 300 participants representing more than 120 organizations
- Represents one of the largest Summit meetings in the history of the Summit
- Goals for this meeting:
 - Discussing the impact of the 2009-2010 H1N1 pandemic
 - Examining the pandemic responses at federal, state, and local levels and building upon lessons learnt to advance seasonal influenza immunization
 - Improving influenza immunization messaging in light of the new universal immunization recommendation from the ACIP

News from the Summit Meeting

- Manufacturers announced their estimated production for the 2010-2011 season
 - 171M doses are estimated to be produced
 - >84M doses likely available by the end of September
 - >150M doses likely available by the end of October
 - GSK: 36M doses
 - MedImmune: 16M doses
 - Merck: 14M doses
 - Novartis: 35-40M doses
 - Sanofi pasteur: 70M doses

News from the Summit Meeting

- CDC discussed new strategies for influenza immunization
 - Capitalize on new partners – schools, new medical specialists, retailers
 - Improve virologic surveillance
 - New ways to approach special populations
 - New venues for immunizations
 - Improved coverage assessment
 - Continue vaccine effectiveness and safety monitoring but at reduced levels from pandemic
 - Implement universal recommendation

News from the Summit Meeting

- Strong interest in improving HCW influenza immunization rates
 - Failure of Health Belief model
 - Ecological models need to be considered
 - Mandates demonstrate 90+% coverage
 - Children's Hospital of Philadelphia – 99.6% coverage
 - BJC Healthcare – 96.8% coverage
 - Honor Roll of successful facilities at:
www.preventinfluenza.org along with resources to aid improvement

News from the Summit Meeting

- Messaging for 2010-2011 season critical
 - Influenza is a serious and unpredictable disease.
 - Everyone 6 months of age and older should be vaccinated for their own protection, the protection of those they love, and for those who are especially vulnerable to the serious and sometimes deadly complications of influenza.
- National Influenza Vaccination Week (NIVW)
 - December 5th through December 11th, 2010